Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Vaccines
•
Allergy & Immunology
Do you consider immunoglobulin replacement in a patient who has rapidly waning vaccine titers but does appropriately respond to revaccination?
Related Questions
Do patients with a PEG allergy have a contraindication to receiving mRNA vaccines?
Why are influenza and COVID vaccines still recommended for patients on immunoglobulin replacement therapy?
Do mRNA vaccines lead to increased rates of acute/chronic urticaria?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
How long do you counsel patients to wait after rituximab therapy before getting live vaccines?
Does splitting the dose of a vaccine during an observed administration affect the efficacy of the vaccine response?
Do you recommend IM Kenalog injection for refractory CRSwNP in a patient already on maximal therapy?
Is immunoglobulin replacement an option for CRS in a patient with normal immune function?
Is omalizumab an option for a patient needing a specific antibiotic with an IgE-mediated reaction who continues to have reactions during a desensitization?
Under what circumstances would you recommend the maternal RSV vaccine for a pregnant patient if nirsevimab will also be available for the infant after birth?
